AmoyDx's Tabrecta (capmatinib) companion diagnostic receives approval in China. The approval covers the Pan Lung panel, which supports MET exon 14 skipping mutation testing.
Amoy Diagnostics laboratories achieved a perfect score in College of American Pathologists proficiency testing for BRCA1/2. Qiming Venture Partners highlighted the result.
AmoyDx and HUTCHMED announce a strategic collaboration to develop companion diagnostics (CDx), including for savolitinib. Announced in 2022, the partnership focuses on advancing MET testing in China.
AmoyDx’s PLC Panel gains MHLW approval in Japan as a companion diagnostic (CDx) for several lung cancer therapies. The announcement dates to 2021 and notes ongoing expansions, but it does not identify the therapies or explain what has expanded.
Amoy Diagnostics listed on the Shenzhen Stock Exchange and began trading under stock code 300685 on August 2, 2017. The IPO raised funds for research and development, new products, and marketing.